Journal of Parkinson's disease最新文献

{"title":"Acknowledgment to reviewers 2024.","authors":"","doi":"10.1177/1877718X241305891","DOIUrl":"https://doi.org/10.1177/1877718X241305891","url":null,"abstract":"","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1680-1682"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease.","authors":"Roy Dayan, Atira S Bick, Caroline Weill, Max Bauer, Halen Baker Erdman, Zvi Israel, Hagai Bergman, Netta Levin, David Arkadir","doi":"10.3233/JPD-240267","DOIUrl":"https://doi.org/10.3233/JPD-240267","url":null,"abstract":"<p><strong>Background: </strong>Compensatory mechanisms in Parkinson's disease (PD) are thought to explain the temporal delay between the beginning of the neurodegenerative process and the appearance of clinical signs. The enhanced structural integrity of the corticospinal tract was previously suggested as one of these mechanisms.</p><p><strong>Objective: </strong>To understand the relations between corticospinal tract integrity and the anatomical, clinical, electrophysiological, and genetic PD characteristics.</p><p><strong>Methods: </strong>We analyzed diffusion tensor imaging (DTI) fractional anisotropy (FA) data from 40 genotyped patients with PD (18 without known genetic cause, 11 with <i>LRRK2</i>-PD and 11 with <i>GBA</i>-PD) who were candidates for subthalamic deep brain stimulation (STN-DBS) and from 25 healthy, age-matched, controls.</p><p><strong>Results: </strong>PD is associated with higher corticospinal FA values (p < 0.001) that are negatively correlated with the disease duration (p = 0.032), confirming previous results. Higher FA values are negatively correlated with cerebral grey matter volumes (p < 0.001) but not with the motor or cognitive PD characteristics, or with the subthalamic beta-oscillatory activity measured intra-operatively. Increased corticospinal FA values are strongly affected by the genetic etiology of PD, with higher values in the monogenic forms of the disease (p < 0.001). The compensatory index, calculated by dividing the corticostriatal FA value by the cerebral grey matter volume, is highest in <i>GBA</i>-PD (p < 0.001) at the time of evaluation for STN-DBS.</p><p><strong>Conclusions: </strong>The genetic etiology of PD strongly shapes corticospinal tract changes along with disease-duration and cerebral grey matter atrophy. The changes may serve as compensatory mechanism.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1584-1593"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials.","authors":"Félix Marchand, Anne-Sophie Blaise, Luc Defebvre, Emeline Cailliau, Stéphanie Bombois, David Devos, Caroline Moreau","doi":"10.1177/1877718X241291996","DOIUrl":"https://doi.org/10.1177/1877718X241291996","url":null,"abstract":"<p><strong>Background: </strong>Progressive supranuclear palsy (PSP) is a rare neurodegenerative disease with diverse clinical phenotypes, prompting the development of new diagnostic criteria known as the MDS-PSP classification. However, little is known about the prognostic value of this classification in order to better stratify patients for the clinical trials.</p><p><strong>Objective: </strong>To assess the impact of the different clinical phenotypes according to the MDS-PSP classification on prognosis using the clinical milestones of death, severe dysphagia, institutionalization, and need for walking aid.</p><p><strong>Methods: </strong>A prospective cohort of 205 PSP patients from Lille University Hospital was analyzed retrospectively. Patients were classified into different MSD-PSP phenotypes according to their clinical presentation after 3 years of follow-up. The milestones of death, severe dysphagia, institutionalization, and need for walking aid were recorded, and a survival analysis was performed to describe the prognosis of each disease presentation.</p><p><strong>Results: </strong>Median survival time was 6.4 (interquartile range (IQR): 4.8-8.6) years and mean diagnostic delay from symptom onset was 38.1 ± 22.5 months. PSP Richardson Syndrome (PSP-RS) had a poorer survival rate and a higher occurrence of severe dysphagia and need for walking aid compared to PSP variants such as PSP Parkinsonism (PSP-P), PSP postural instability without ocular motor dysfunction (PSP-PI), and other rare phenotypes.</p><p><strong>Conclusions: </strong>PSP-RS has a less favorable prognosis compared to PSP variants stratified according to the MDS-PSP classification. This classification could assist in selecting patients for clinical trials and help design outcomes that account for the disease heterogeneity.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1652-1658"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of serotonin reuptake and serotonin-noradrenaline reuptake inhibitors on motor symptoms in Parkinson's disease: A PPMI-based matched-subject study.","authors":"Teodora Matić, Martijn Hendriks, R Saman Vinke, Aleksander Sadikov, Dejan Georgiev","doi":"10.1177/1877718X241296016","DOIUrl":"https://doi.org/10.1177/1877718X241296016","url":null,"abstract":"<p><p><b>Background:</b> Depression often co-occurs with Parkinson's disease (PD) and is effectively treated with selective serotonin reuptake inhibitors (SSRI) and serotonin and noradrenaline reuptake inhibitors (SNRI), but their effect on motor symptoms has not yet been conclusively demonstrated. <b>Objective:</b> To assess the impact of the SSRI/SNRI on the motor symptoms of PD. <b>Methods:</b> We used data from the Parkinson's Progression Markers Initiative database, in a matched subject design with a target group (N = 47) which had been taking SSRI/SNRI medication and a control group (N = 90) which had not. Matching criteria included Movement Disorders Society Unified Parkinson's Disease Rating Scale part III (MDS-UPDRS-III) total score and its subscales' scores, and levodopa equivalent daily dose (LEDD) at the time of the first examination (initial LEDD). For the target group, we compared the MDS-UPDRS-III score before and after taking the SSRI/SNRI medication, while for the control group we compared two equally spaced examinations. <b>Results:</b> In the target group, we found a greater worsening of motor scores, which was associated with lower values of initial LEDD. In addition, apathy was an independent predictor of motor worsening. <b>Conclusions:</b> SSRI/SNRI-use seems to be characterized by a steeper worsening of motor symptoms, which can be predicted by a lower initial LEDD. Further research should continue to investigate the effect of SSRI/SNRI-use on motor symptoms in PD.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1642-1651"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CSF GPNMB in Parkinson's disease: A potential association with age and microglial activation.","authors":"Xi-Chen Zhu, Yasuaki Mizutani, Reiko Ohdake, Harutsugu Tatebe, Toshiki Maeda, Sayuri Shima, Akihiro Ueda, Mizuki Ito, Shinji Ito, Takahiko Tokuda, Hirohisa Watanabe","doi":"10.1177/1877718X241288712","DOIUrl":"https://doi.org/10.1177/1877718X241288712","url":null,"abstract":"<p><strong>Background: </strong>Recent evidence suggests a link between glycoprotein non-metastatic melanoma protein B (GPNMB) and Parkinson's disease (PD) pathogenesis. Although elevated plasma GPNMB levels associated with disease severity have been reported in PD, cerebrospinal fluid (CSF) alterations remain elusive.</p><p><strong>Objective: </strong>To explore CSF GPNMB alterations and its clinical significance in PD.</p><p><strong>Methods: </strong>This study enrolled 118 sporadic PD patients and 40 controls. We examined the potential associations between CSF GPNMB levels and the clinical characteristics or biomarkers of neurodegenerative pathogenesis.</p><p><strong>Results: </strong>PD patients had higher CSF GPNMB levels than controls (<i>p </i>= 0.0159). In the PD group, CSF GPNMB levels correlated with age (age at examination: <i>r_s</i>= 0.2511, <i>p </i>= 0.0061; age at onset: <i>r_s</i>= 0.2800, <i>p </i>= 0.0021) and the severity of motor and cognitive dysfunction (MDS-UPDRS III score: <i>r_s</i>= 0.1998, <i>p </i>= 0.0347; Mini-Mental State Examination score: <i>r_s</i>= -0.1922, <i>p </i>= 0.0370). After correcting for multiple comparisons, the correlation with age at onset remained significant. CSF GPNMB levels were also positively correlated with CSF soluble triggering receptor expressed on myeloid cells 2 (sTREM2) levels in both the PD (<i>r_s</i>= 0.3582, <i>p </i>< 0.0001) and control (<i>r_s</i>= 0.4743, <i>p </i>= 0.0023) groups. Furthermore, multiple regression analysis revealed CSF sTREM2 level as the strongest determinant of CSF GPNMB levels in the PD group (t-value = 3.49, p = 0.0007).</p><p><strong>Conclusions: </strong>Elevated CSF GPNMB levels, linked with age and microglial activation, may be a valuable marker for understanding the interplay between aging, neuroinflammation, and PD pathology.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1533-1542"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Festination-like steps during forward and backward gait while playing tennis.","authors":"Bruno Bergmans, Pieter Ginis, Bastiaan R Bloem, Alice Nieuwboer","doi":"10.1177/1877718X241291983","DOIUrl":"https://doi.org/10.1177/1877718X241291983","url":null,"abstract":"<p><p>Festination is an episodic gait disorder which is often a precursor of freezing of gait episodes in Parkinson's disease patients. We discuss what lessons can be learned from a patient who had to quit playing tennis as he repeatedly fell due to backward festination-like steps.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1677-1679"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"mHealth-assisted expiratory muscle strength training in Parkinson's disease patients: A proof-of-concept study.","authors":"Martin Srp, Álvaro Sánchez Ferro, Joaquim Ferreira, Ricardo Cacho, Laura Antunes, Raquel Bouça-Machado, Ota Gál, Martina Hoskovcová, Radim Kliment, Jan Mužík, Tiago A Mestre, Daniel Pérez Rangel, Evžen Růžička, iCARE-Pd Consortium","doi":"10.1177/1877718X241296013","DOIUrl":"https://doi.org/10.1177/1877718X241296013","url":null,"abstract":"<p><strong>Background: </strong>Expiratory muscle strength training (EMST) is acknowledged for its therapeutic benefits in Parkinson's disease (PD), yet long-term adherence remains a challenge.</p><p><strong>Objective: </strong>The primary aim of this study was to assess the preliminary effects of EMST coupled with a mobile health app (SpiroGym) on self-efficacy and exercise adherence in PD patients. The secondary aim was to assess the usability of the SpiroGym app.</p><p><strong>Methods: </strong>This single-group, multicenter, multinational proof-of-concept study involved 63 PD patients across four tertiary PD centers. Participants were enrolled in either a 1-week (n = 35) or 24-week (n = 28) EMST program coupled with SpiroGym app. Self-efficacy was assessed using the Self-Efficacy for Home Exercise Program scale (SEHEPS) and exercise adherence was monitored by SpiroGym app. Usability was evaluated using the System Usability Scale.</p><p><strong>Results: </strong>Post-intervention, significant improvements in SEHEPS were observed in 1-week group (d = 0.48; p = 0.02) and 24-week group (d = 0.57; p = 0.002). Adherence rates in the 24-week PD patient group were high throughout the course of the study. Post-training SEHEPS was found to correlate (rho = 0.55; adjusted p = 0.016) with adherence to EMST during the non-supervised maintenance phase. The SpiroGym app exhibited high usability (>85th percentile score), with no significant differences noted between short-term and long-term use, indicating sustained user satisfaction.</p><p><strong>Conclusions: </strong>The results of our study suggest a promising role for SpiroGym app in supporting adherence to home-based EMST in PD patients. Nevertheless, future comparative studies are required to confirm SpiroGym's effectiveness.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1623-1630"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acknowledgment to reviewers 2024.","authors":"","doi":"10.1177/1877718X241305891","DOIUrl":"https://doi.org/10.1177/1877718X241305891","url":null,"abstract":"","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1680-1682"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pediatric-onset <i>PRKN</i> disease: New insights into an understudied population.","authors":"Ozge Gonul Oner, Céline Biboulet Bruneau, Valérie Fraix, Véronique Bourg, Luc Defebvre, Eugénie Mutez, Emmanuel Roze, Cécile Laroche, Matthieu Béreau, Marie-Ange Nguyen-Morel, Elena Moro","doi":"10.1177/1877718X241296153","DOIUrl":"https://doi.org/10.1177/1877718X241296153","url":null,"abstract":"<p><strong>Background: </strong>In pediatric age, the <i>PRKN</i> mutation is reported as one of the most common genetic causes of Parkinson's disease. However, detailed clinical data on <i>PRKN</i> patients with pediatric onset are scarce.</p><p><strong>Objective: </strong>To describe clinical characteristics, disease progression, and management of <i>PRKN</i> patients with pediatric onset.</p><p><strong>Methods: </strong><i>PRKN</i> patients with onset of clinical signs before the age of 18 years were included in this retrospective multicenter study. Collected data included detailed clinical characteristics, progression, and disease management. Data presentation is descriptive due to the sample size.</p><p><strong>Results: </strong>Nine patients (five females) were included from five French movement disorders centers. The mean age at symptom onset was 10.78 ± 2.22 years (median, 11; range, 7-14). Dystonia was the first most common motor symptom (six patients). The mean time from symptom onset to genetic diagnosis was 13.33 ± 9.21 years (median, 11; range, 3-32). The most commonly reported non-motor symptoms were sleep disorders (seven patients), anxiety (six patients), and depression (five patients). The first treatment was L-dopa in four patients, dopamine agonist in two, carbamazepine in two, and rasagiline in one. Dyskinesia and impulse control disorders were the most common treatment-related side effects (nine and six patients, respectively). Four patients underwent deep brain stimulation surgery. The last available follow-up was at 27.22 ± 14.05 years (median, 28; range, 6-56) after the diagnosis.</p><p><strong>Conclusions: </strong>This is the first study reporting detailed clinical features and long-term management of <i>PRKN</i> patients with pediatric onset. Prompt diagnosis and appropriate treatment strategies are important to optimize disease management.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1631-1641"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143432836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Subthalamic and nigral stimulation for freezing of gait in Parkinson's disease: Randomized pilot trial.","authors":"Carlo Alberto Artusi, Claudia Ledda, Silvia Gallo, Domiziana Rinaldi, Corrado Campisi, Vanessa Rousseau, Claire Thalamas, Raquel Barbosa, Fabienne Ory-Magne, Christine Brefel-Courbon, Olivier Rascol, Amaury de Barros, Estelle Harroch, Maurizio Zibetti, Mario Giorgio Rizzone, Alberto Romagnolo, Gabriele Imbalzano, Leonardo Lopiano, Jean Luc Houeto, Margherita Fabbri","doi":"10.1177/1877718X241292315","DOIUrl":"https://doi.org/10.1177/1877718X241292315","url":null,"abstract":"<p><strong>Background: </strong>Freezing of gait (FoG) is a debilitating symptom of Parkinson's disease (PD) with limited response to dopaminergic medication and subthalamic deep brain stimulation (STN-DBS). Substantia nigra pars reticulata (SNr) stimulation could improve FoG.</p><p><strong>Objective: </strong>To analyze the effect of combined STN-SNr stimulation at different frequencies on FoG.</p><p><strong>Methods: </strong>We performed a double-blind, cross-over, randomized pilot trial involving STN-DBS treated PD patients with FoG. Participants received: high-frequency (HF) STN-DBS (S), combined HF-STN and SNr stimulation (C1), and combined HF-STN and low-frequency (LF) SNr stimulation (C2), for one month each. The primary endpoint was the score change in the New-Freezing-of-Gait-Questionnaire (NFOG-Q). Secondary analyses were performed on motor complications, axial symptoms, daily living activities, psychiatric symptoms, sleep, and patient preference.</p><p><strong>Results: </strong>Fifteen patients received at least one combined stimulation. No significant difference in NFOG-Q scores was found between S, C1, and C2; one-third of patients showed a clinically significant improvement (≥8 points) with combined stimulations. Motor complications improved significantly with C1 and C2 (C1-S: 3.6 ± 3.8 vs. 4.9 ± 3.8, p = 0.046; C2-S: 2.7 ± 3.1 vs. 4.9 ± 3.8, p = 0.005). 80% of patients preferred the combined STN-SNr stimulation while blinded. All adverse events were manageable.</p><p><strong>Conclusions: </strong>Our study did not prove a statistically significant improvement in NFOG-Q with STN-SNr stimulation; however, one-third of patients experienced a clinically meaningful FoG improvement, and the majority preferred to maintain STN-SNr stimulation. STN-SNr stimulation was both safe and effective in addressing motor complications and improving sleep quality, highlighting the importance of further exploration into the effects of combined STN-SNr stimulation.</p>","PeriodicalId":16660,"journal":{"name":"Journal of Parkinson's disease","volume":"14 8","pages":"1602-1613"},"PeriodicalIF":4.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143433134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}